In all living organisms, gene expression is modulated by proteins and sRNAs. sRNAs have been identified in many bacteria, and a few act by binding and modulating protein activity. The majority of sRNAs function by pairing with target mRNAs, modifying mRNA transcription, stability and/or translation 1 . These base-pairing sRNAs fall into two categories: trans-and cis-encoded sRNAs. The trans sRNAs are encoded at genomic locations distant from the mRNAs they regulate and share only limited complementarities with their targets. The cis-encoded asRNAs are transcribed from the DNA strand opposite another gene and have perfect complementarities with their target. Recently, a considerable amount of natural asRNAs has been detected in various organisms, including human cells 2 .
In all living organisms, gene expression is modulated by proteins and sRNAs. sRNAs have been identified in many bacteria, and a few act by binding and modulating protein activity. The majority of sRNAs function by pairing with target mRNAs, modifying mRNA transcription, stability and/or translation 1 . These base-pairing sRNAs fall into two categories: trans-and cis-encoded sRNAs. The trans sRNAs are encoded at genomic locations distant from the mRNAs they regulate and share only limited complementarities with their targets. The cis-encoded asRNAs are transcribed from the DNA strand opposite another gene and have perfect complementarities with their target. Recently, a considerable amount of natural asRNAs has been detected in various organisms, including human cells 2 .
In bacteria, antisense transcription was first demonstrated almost 50 years ago and was considered to be the exception to the rule. However, accumulating evidence from transcriptome studies suggests that extensive antisense transcription occurs in bacteria, producing many cis-sRNAs of various sizes 3 . In the human pathogen Helicobacter pylori, asRNAs has been detected for 46% of all annotated open reading frames 4 , indicating that bacterial transcriptomes are unexpectedly complex. The functional relevance of this massive antisense transcription, however, is poorly understood, but these asRNAs are predicted to have substantial, yet mostly unexplored, impacts on gene expression. Also, information on the molecular mechanisms of individual asRNAs is growing at a slow pace. In bacteria, mechanisms of asRNA action include alteration of target RNA stability, transcription interference or termination, as well as translation modulation 3 .
The Gram-positive bacterium S. aureus is a major human pathogen that causes a wide spectrum of nosocomial and community-associated infections with high mortality. S. aureus generates a large number of virulence factors, whose timing and expression levels are precisely tuned by regulatory proteins and sRNAs. S. aureus expresses at least 91 sRNAs 5 , including asRNAs. Recent high-resolution transcriptome analysis has detected a large proportion of these asRNAs among the inventoried S. aureus sRNAs [6] [7] [8] [9] . In S. aureus, many asRNAs are expressed from pathogenicity islands and mobile elements including plasmids and transposons. Although the S. aureus pathogenicity islands are the repository of toxins, adherence factors, invasion factors, superantigens and secretion systems, the location of sRNAs in the pathogenicity islands suggests that they have important roles during S. aureus infections. In addition to all the RNAs expressed from the pathogenicity islands 6 , at least four asRNAs are also expressed 5 . One of these asRNAs, Teg152, was previously detected in strain N315 by high-throughput sequencing 10 and is predicted, based on its overall genomic location, to be complementary with the SprA1 3′ end. Because Teg152 was found to act as a functional asRNA against SprA1, as reported here, it was renamed SprA1 AS . Sequence comparisons suggest that the SprA1-SprA1 AS pair forms a type I toxin-antitoxin module 11 . SprA1 was previously identified by computer searches combined with transcriptomic analysis and its expression verified by northern blots 6 . The sprA gene is present in two to five copies in the bacterial chromosome and in plasmids, depending on the strains. We set out to answer the question: what are the biological roles of the SprA1-SprA1 AS pair in S. aureus ? We provide evidence that a cis-encoded RNA functions in trans. During S. aureus growth, SprA1 AS and SprA1 are constitutively and concomitantly expressed, and the asRNA forms a complex with SprA1 in vivo to prevent internal translation of the SprA1-encoded open reading frame (ORF) by occluding its translation initiation signals through pairing interactions. Whereas the 60-nucleotide (nt) SprA1 AS is made of two stem-loops, the 208-nt SprA1 contains two RNA pseudoknots, including an internal ORF. Polypeptide translation is naturally disfavored by the SprA1 secondary structure, in which 1 0 6 VOLUME 19 NUMBER 1 JANUARY 2012 nature structural & molecular biology a r t i c l e s its Shine-Dalgarno sequence is sequestered within a 5′ stem-loop. The SprA1 peptide lyses human cells, and upon SprA1 AS binding, an internal RNA pseudoknot of SprA1 unfolds and forms a helix with SprA1 AS . Structural evidence supported by mutational analysis of the RNAs indicate that the functional domain of SprA1 AS is outside its 3′ complementary sequence with SprA1. Functional domains of antisense RNAs can be located outside from their target gene complementary sequences, making it arduous to elucidate the mechanisms of asRNA-based gene regulation, no matter which kingdom of life is studied.
RESULTS

Expression of SprA1 and SprA1 AS
Up to five copies of sprA have been detected in the S. aureus strains 6 . In strain Newman, a human clinical isolate, only two copies, sprA1 and sprA2, have been identified. Therefore, that strain is a simplified model for studying the multicopy sprA gene. In Newman, we found sprA1 to be located in the νΣαβ pathogenicity island 12 , between a transposase and a hypothetical protein (Fig. 1a) . We also detected an antisense RNA to SprA1, identified in strain N315 by high-throughput sequencing 10 . The sprA1 and sprA1 AS genes read in opposite directions, with a predicted sequence overlap at their 3′ ends (Fig. 1a) . We detected a second copy, sprA2, in the core genome at position 2560389-2560600, between a hypothetical protein and a protein from the GtrA family (not shown). sprA1 and sprA2 shared 74% nucleotide identity. Using a DNA probe specific for SprA1, we demonstrated that the SprA1 is expressed in Newman, as well as its asRNA SprA1 AS (Fig. 1b) .
To distinguish between the expression of the two copies of sprA and to assess their functional implications independently of one another, we constructed an sprA1-sprA1 AS deletion mutant (∆sprA1-sprA1 AS ) in Newman by homologous recombination. SprA1-and SprA1 AS -specific DNA probes confirmed the absence of expression of both SprA1 and SprA1 AS in the deletion strain (Fig. 1b, right panel) . Quantification of the expression levels of SprA1 and of SprA2 indicated that in the Newman strain, SprA1 is expressed two-to three-fold more times than SprA2 (data not shown). This report focuses on the functional investigation of the SprA1 and SprA1 AS RNAs.
Nucleotide overlap between SprA1 and SprA1 AS Determining SprA1 and SprA1 AS 5′ and 3′ boundaries was required for subsequent functional and structural analysis. Although they are predicted to overlap, the extent of sequence overlay between the two RNAs was assessed experimentally in Newman. For SprA1, this was resolved using rapid amplification of cDNA ends (RACE), as described 13 , combined with direct size assessment using northern blots on polyacrylamide gels (Fig. 1b, left panel) .
The SprA1 5′ end maps at position G1889597 in strain Newman (and at G1856485 in strain N315, data not shown), twelve nucleotides downstream from a (−12)TATAAT(−7) box (specified 5′→3′) that is the predicted promoter ( Supplementary Fig. 1a, boxed) . The SprA1 3′ end forms an intrinsic terminator characterized by a stem loop (H6, Supplementary Fig. 1a) followed by an imperfect U-tract (5′-UUGGUGU-3′). In E. coli, about half of the Rho-independent terminators possess an imperfect U-tract 14 .
The ends of SprA1 AS were very difficult to assess experimentally because its small size precluded us from using RACE on circularized RNAs 15 . Therefore, the SprA1 AS transcriptional start site was resolved by primer extension analysis on total RNAs from wild-type Newman cells containing a pCN35ΩsprA1 AS plasmid expressing SprA1 AS from its endogenous promoter, to bypass the obstacle created by its small size. We verified that SprA1 AS expressed in vivo from the plasmid has a similar length to that of wild-type SprA1 AS . The SprA1 AS 5′ end was assigned to position G1889770 (Supplementary Fig. 2a) . Therefore, the SprA1 AS 5′ end is positioned ten nucleotides downstream from a (−10)TATAAT(−5) box (specified 5′→3′) that is its predicted promoter ( Supplementary Fig. 1b, boxed) . The SprA1 AS 3′ end forms an intrinsic transcription terminator characterized by a stem loop (H2 AS , Supplementary Fig. 1b) , followed by a near-perfect U-tract Figure 1 a r t i c l e s (5′-UUUUUAUU-3′, Supplementary Fig. 1b ). SprA1 AS is an ~60-nt asRNA. The experimental determination of the two RNA boundaries allowed us to produce both synthetic transcripts.
Phylogenetic distribution of sprA1 and sprA1 AS genes
We studied the phylogenetic distribution of sprA1 and sprA1 AS in all sequenced bacterial genomes. We identified the genes encoding SprA1 and SprA1 AS in two orders of the class Bacilli: Bacillales (Staphylococcaceae, genus Staphylococcus) and Lactobacillales (Enterococcaceae, genus Enterococcus). We distinguished them from the sprA2 that is in the core genome by their locations within the pathogenicity islands. Sequence alignments of SprA1 AS indicate sequence conservation in the non-overlapping region of the RNA pair, corresponding to ~20 nucleotides at the 5′ side of the RNA. Within all the S. aureus species in which we detected the RNA pair, the two genes were conserved at the nucleotide level, suggesting selective pressure ( Supplementary Fig. 1 , only four S. aureus sequences shown). Within the genus Staphylococcus, however, there were differences scattered through the RNA sequence.
SprA1 and SprA1 AS expression profiles during growth
We monitored SprA1 and SprA1 AS expression levels by northern blotting during growth of the S. aureus strain Newman (Fig. 1c,d) .
We quantified the expression levels of these asRNAs relative to the transfer-messenger RNA (tmRNA), a ubiquitous eubacterial sRNA expressed at constant levels during growth. SprA1 was constitutively expressed, and it was detected early and present at all phases. SprA1 AS was also expressed early and reproducibly showed an expression peak at the mid-exponential phase, and it was also expressed later. We also observed similar expression patterns for the two RNAs in SH1000 and N315 S. aureus strains (data not shown). The in vivo concentrations of SprA1 and SprA1 AS in the wild-type Newman strain were determined by including a range of each of the purified synthetic RNAs in the northern blots, for quantitative estimations (Fig. 1e) . At all times during growth, SprA1 AS was found in excess quantities relative to SprA1, ranging from 35-mol to ~90-mol in excess of SprA1 (Fig. 1e) .
In vivo detection and binding of the SprA1-SprA1 AS duplex
Although the two RNA genes partially overlapped, we tested experimentally whether the two RNAs SprA1 and SprA1 AS interacted in vivo. For that purpose, a 46-base streptomycin-binding aptamer 16 (StreptoTag, ST) was fused at the 5′ end of the sprA1 gene and cloned into a pCN35ΩSTsprA1-SprA1 AS plasmid expressing 5′ Strepto Tag-SprA1 (STSprA1) and SprA1 AS from their endogenous promoters. The ∆sprA1-∆sprA1 AS Newman strain was complemented with the pCN35ΩSTsprA1-sprA1 AS plasmid, and northern blots demonstrated that STSprA1 is expressed in the complemented strain at both midexponential (A 600nm = 3) and early stationary (A 600nm = 11) growth phases ( Fig. 2a ; STSprA1 is expressed to higher levels than WT SprA1 in vivo because of the plasmid copy number). For the controls, the expression of SprA1 in WT cells, but not in the deletion strain, was monitored, and the size difference between STSprA1 and WT SprA1 corresponded to the 46-nt StreptoTag. Total RNAs extracted from Newman ∆sprA1-∆sprA1 AS -pCN35Ω STsprA1-sprA1 AS cells were loaded onto a streptomycin affinity matrix. As shown by PAGE ( Supplementary Fig. 2b ), the flow through fraction contained the nonspecific RNAs (tRNAs and ribosomal RNAs), the last two washes caused some loss of STSprA1 from the column, and notably, the elution carried out with 100 µM streptomycin contained STSprA1 and SprA1 AS ( Supplementary Fig. 2b ), indicating that SprA1 AS was in complex with immobilized STSprA1. For a negative control, we extracted total RNAs from Newman WT pCN35ΩsprA1 AS cells and loaded them onto the affinity matrix. Northern blots demonstrated that in the absence of STSprA1 in vivo, SprA1 AS could not bind the column by itself and was only detected in the flow through fraction, together with a nonspecific sRNA, tmRNA (Fig. 2b) . However, with the ∆sprA1-∆sprA1 AS -pCN35Ω STsprA1-sprA1 AS cells, northern blots demonstrated that the eluted fraction contained both SprA1 AS and STSprA1, but not tmRNA (Fig. 2b) . Altogether, these experiments indicate that SprA1 forms a complex with SprA1 AS in vivo and that its 5′ StreptoTag does not hamper recognition. We analyzed duplex formation between SprA1 and SprA1 AS by gel-retardation assays. The SprA1-SprA1 AS duplex was detected at a 1:0.3 molar ratio, and all SprA1 was in complex with SprA1 AS at a 1:1 molar ratio (Fig. 2c) . Complex formation between labeled SprA1 and SprA1 AS was also analyzed, and nearly all labeled SprA1 was in complex at a 1:1 molar ratio (Fig. 2d) . In the two experiments, the binding was specific, although a 1,000-fold molar excess of total tRNAs did not displace SprA1 AS or SprA1 from preformed SprA1 ASSprA1 complexes, whereas a 20-fold excess of unlabeled SprA1 AS (Fig. 2c,d ), a value that was mandatory for complex formation between the two RNAs that we subsequently analyzed by structural probes in solution.
Structural interaction between SprA1 and SprA1 AS
We analyzed conformations of free SprA1 and SprA1 AS (Supplementary Fig. 3 ) as well as the SprA1-SprA1 AS duplexes ( Supplementary Figs. 4 and 5) by structural probes (lead, RNAse V1 and nuclease S1). The data are summarized in the SprA1 and SprA1 AS models. SprA1 AS has two folded stems (H1 AS and H2 AS ) separated by an 8-nt junction (H1-H2 AS ). Our sequence alignments provide strong phylogenetic evidence for stem H1 AS , but not for H2 AS (Supplementary Figs. 1b and 5b) . In SprA1, the presence of ribonuclease V 1 cuts with no S 1 or lead cuts supports the existence of six stems, H1 to H6. Our probing data support the existence of two loops, L1 and L6, capping H1 and H6, respectively ( Supplementary  Fig. 3b,c) . The existence of internal bulges within H1 and H6 is supported by the presence of nuclease S 1 and lead cleavages. A 5-nt junction separates H1 from the first pseudoknot, PK1 (H2-L2-H3-L3), adjoining PK2 (H4-L4-H5-L5). SprA1 is a compact RNA made of two tandem pseudoknots flanked by two stable helices, the second acting as a transcription terminator. Our sequence alignments provide strong phylogenetic support for the H1-H6 stem but not for H3 (Supplementary Figs. 1a and 5a) .
We examined the structural changes induced by duplex formation between the two RNAs. Upon SprA1 binding, the most marked reactivity changes involved the single-stranded H1-H2 AS junction that was cleaved by RNase V1 and protected from lead cuts, suggesting that it becomes double stranded upon duplex formation ( Fig. 3 and Supplementary Figs. 4 and 5c ). An overall destabilization of the RNA was highlighted by the absence of V1 cuts in H1 AS and H2 AS , as well as by the fading of S1 and lead cuts in L1 AS and L2 AS . Conversely, in the presence of SprA1 AS , all the reactivity changes in SprA1 were centered between the lower portions of H1 and PK1, indicating that SprA1 becomes double-stranded as it becomes protected from lead and S1 cuts ( Fig. 3 and Supplementary Fig. 4a) . Notably, there are no structural changes at the cis-overlapping region between the two RNAs. Altogether, the probing data we collected on the SprA1-SprA1 AS duplex support an interaction between the two RNAs, as presented in Figure 3 . Comparing sequences from genomes and plasmids provided phylogenetic support for the interaction (covariations in Fig. 3b ).
SprA1 and SprA1 AS interact by non-overlapping domains
Between SprA1 and SprA1 AS , there is an intuitive binding site that involves a 35-nt overlap at their 3′ ends (Fig. 3c,d, yellow) . Experimental evidence supports a different, unexpected binding site that involves pairings between nucleotides located at their 5′ domains (Fig. 3, red) . To assess the contribution of those binding sites in duplex formation, we cleaved SprA1 and SprA1 AS into two halves to retain a single binding domain on each RNA variant (5′ SprA1, 3′ SprA1, 5′ SprA1 AS and Supplementary Fig. 6 ). We analyzed duplex formation between each of these shorter RNAs by gel-retardation assays (Fig. 4 and Supplementary Fig. 2d) . A specific 5′ SprA1-SprA1 AS duplex was detected (Fig. 4a) with a K d similar to that observed for wild-type SprA1 (Fig. 2c,d) , whereas the 3′ SprA1 construct was unable to bind SprA1 AS , even at a 20-fold molar excess (Fig. 4b) , indicating that the SprA1 5′ domain, including H1-L1 and PK1, is necessary and sufficient to interact with SprA1 AS . Also, a specific 5′ SprA1 AS -5′ SprA1 duplex was detected (Supplementary Fig. 2d ) with a weaker affinity than that between the two native RNAs (Fig. 2c,d) , probably because of two conformations for PK1 from 5′ SprA1 (Supplementary Fig. 2d, two bands in the control lane), including open and closed pseudoknotted structures. In addition, a specific 5′ SprA1 AS -SprA1 duplex was detected (Fig. 4c) , but its apparent K d was much higher than that between the two native RNAs, probably because of the reduced stability of 5′ SprA1 AS without the H2 AS terminal helix and also because of the reduced accessibility of the folded PK1 in full-length SprA1. Reciprocally, the 3′ SprA1 AS construct was unable to bind SprA1, even at a 200-fold molar excess (Fig. 4d) . Overall, our work shows that the non-overlapping 5′ domains of each RNA are necessary and sufficient for duplex formation, whereas the complementary 35 nucleotides at the SprA1 and SprA1 AS 3′ ends are dispensable for duplex formation. Fig. 6 ). 
SprA1 AS non-overlapping domain represses SprA1 translation
In all the sprA1 genomic sequences, an internal ORF was identified ( Supplementary Fig. 1a, green) that was predicted to encode a 30-33 amino acid (aa) peptide, starting at 51-GUG-53 or 54-AUG-56 initiation codons and ending at a 144-UAG-146 stop codon. Moreover, an internally conserved 37-AGGAGG-42 Shine-Dalgarno sequence was identified 8-11 nucleotides upstream of the predicted start codons (Fig. 5a) . (All sequences are specified 5′→3′.) To test whether or not ribosomes can form translation initiation complexes on SprA1, toeprint assays were carried out on ternary initiation complexes, including purified 70S ribosomes from S. aureus, initiator tRNA fMet and SprA1. In the presence of the purified S. aureus ribosomes, toeprints were detected on SprA1 at C65-C69 within L2 from pseudoknot PK1, 14-18 nucleotides downstream from the predicted initiation codons (Fig. 5b) . The presence of multiple toeprints suggests that ribosome loading onto SprA1 takes place at several positions, probably because of two available initiation codons and despite the fact that there is a compact pseudoknot structure at the loading site, which has to be opened by the ribosomes. Within SprA1, the predicted ShineDalgarno sequence was mutated into 37-UCCUCC-42 and, to maintain the conformation of helix H1, 5-CCUAUCU-11 was also mutated into 5-GGAAGGA-11 (Fig. 5a) . The ribosomes were unable to load onto this SprA1 variant, which we named the SD-mutated SprA1 (Fig. 5b, right panel) , demonstrating that the 37-AGGAGG-42 sequence is required for translation initiation. (All sequences are specified 5′→3′.) Although the interaction between SprA1 AS and SprA1 (Fig. 3) coincides with the region covered by the ribosomes during translation initiation, SprA1 AS should prevent ribosome loading onto SprA1. Indeed, in the presence of SprA1 AS , SprA1 toeprints disappeared (Fig. 5b) , indicating that the asRNA prevents ribosome loading onto SprA1. Notably, a strong stop is detected at U61 within the SprA1 structure, probably because RNA duplex formation induces a conformational change (Fig. 3) . We carried out in vitro translation assays to provide direct experimental evidence that SprA1 can express a polypeptide predicted to contain 31 amino acids (Supplementary Fig. 7 ). In the presence of wild-type SprA1, a 2-to 5-kDa polypeptide was detected (Fig. 5c) , in agreement with the ~3.45 kDa theoretical molecular weight of WT SprA1. When SprA1 AS was added into the reaction mixture (at a two-fold molar excess compared to SprA1), SprA1 translation was blocked. We conclude that SprA1 AS downregulates SprA1 translation by direct pairing interactions at and around the SprA1 translation initiation signals (Fig. 3) . We added a ten-fold molar excess of either 5′ SprA1 AS or 3′ SprA1 AS in the translation assays of SprA1 and found that 5′ SprA1 AS has a weaker binding affinity for SprA1 than WT SprA1 AS has (Figs. 2c,d and 4c) . Whereas 5′ SprA1 AS reduced SprA1 translation substantially, 3′ SprA1 AS did not (Fig. 5c) , providing direct evidence that SprA1 AS prevents SprA1 translation by its 5′ domain, but not by its 3′ domain. As a negative control, the SD-mutated SprA1 could not be translated in vitro (Fig. 5c) , in agreement with the toeprint data, as it failed to recruit the S. aureus ribosomes (Fig. 5b, right panel) . Altogether, these experiments indicate that SprA1 AS binds SprA1 at its 5′ non-overlapping sequence to Fig. 7 ).
a r t i c l e s block internal translation of SprA1. To assay if SprA1 AS also regulates SprA1 transcription and/or stability, in addition to its translational control, SprA1 AS was overexpressed in vivo, and the expression levels of SprA1 were monitored by northern blots during bacterial growth. Increasing the expression levels of SprA1 AS did not substantially affect SprA1 levels in vivo, ruling out a direct regulation at the RNA level (Fig. 5d) .
SprA1 peptide is repressed in trans by cis-SprA1 AS in vivo
For the data presented above, the sprA1 and sprA1 AS genes were linked physically. Genetically decoupling the location and expression of the two overlapping RNAs was required to demonstrate in vivo that a cis-sRNA operates in trans. The SprA1 peptide had very low immunogenicity (data not shown), and its overexpression in vivo inhibited S. aureus growth (data not shown). We designed a reporter peptide construct by combining the 5′ sequence of SprA1 that included, at the N terminus, 20 amino acids from its internal coding sequence, and detected it by merging it with a 22-aa 3× Flag sequence. Peptide truncation at the C terminus was required to lower the toxicity of SprA1 in vivo. Also, we replaced the transcription terminator sequence of SprA1 that overlaps with SprA1 AS by another, unrelated terminator sequence (blaZ). We used a low-copy (~20 copies per bacterium) vector (pCN34), and transformed the pCN34ΩsprA1tag into Newman ∆sprA1-∆sprA1 AS . Immunoblots using anti-Flag antibodies demonstrated that the SprA1 fusion peptide was expressed in vivo (Fig. 6a) . To monitor the impact of SprA1 AS on the SprA1-encoded fusion peptide in vivo, we transformed strain ∆sprA1-∆sprA1 AS pCN34ΩsprA1tag with either pCN35 or pCN35ΩsprA1 AS . In the strain containing the two RNAs in trans, each expressed from a different plasmid, SprA1 peptide levels were markedly reduced (Fig. 6a) , demonstrating the downregulation of the SprA1 peptide expression by SprA1 AS in vivo. Northern blots validated the presence of the SprA1-flagged and SprA1 AS RNAs in the ∆sprA1-∆sprA1 AS double-deletion strain containing the two plasmids, whereas, as expected, there was only the SprA1-flagged RNA in the ∆sprA1-∆sprA1 AS pCN34ΩsprA1tag strain transformed with the empty pCN35 plasmid (Fig. 6b) . We conclude that SprA1 AS prevents SprA1-encoded peptide expression in trans in vivo and that its 3′ end overlapping region with SprA1 is dispensable for regulation.
The SprA1-encoded peptide is cytolytic for human cells Sequence alignments of the SprA1-encoded peptide indicated α-helicity and amphipathy (Supplementary Fig. 7) , which are features of pore-forming peptides 17 . We demonstrated the lytic activity of the SprA1 peptide by adding increasing concentrations of the chemically synthesized peptide to human erythrocytes (Fig. 7a) . The SprA1 peptide lysed human erythrocytes at a 1-µM concentration and above, but was less active toward sheep erythrocytes (Fig. 7b) , suggesting a narrow hemolytic range. Some microbial hemolysins show antibacterial activity 18 . We found that the SprA1 peptide also has antimicrobial activity against Gram-negative and Gram-positive bacteria (data not shown). The bactericidal activity of the SprA1 peptide against S. aureus cells explains why SprA1 AS is continuously expressed during bacterial growth, preventing SprA1 translation and toxicity against S. aureus cells.
DISCUSSION
Many asRNAs have recently been inventoried in bacteria and eukaryotes, but the molecular mechanisms underlying their functions are, for the most part, unknown. By definition, cis-asRNAs regulate the genes encoding the respective opposite strands 19 . It is commonly accepted that cis-asRNA functions are linked to their sequence overlap with genes transcribed from the opposite DNA chain. We report a case of an asRNA that acts as a trans-regulator in S. aureus. This case demonstrates that asRNAs can interact in trans with complementary target genes, and possibly also with other genes, at remote genetic loci. Base complementarities between overlapping RNAs do not necessary imply that they are the functional unit of the pair. Because cis-RNAs can work in trans, the distinction between cis-and trans-RNAs should be revised. Our findings also suggest that the mechanisms of gene regulation of the identified asRNAs should be re-evaluated, as some could operate in trans on targets. It may be advantageous for trans-sRNAs to be located in cis on the chromosome because during genomic rearrangements they will move with their target genes. In many bacteria, trans-acting sRNAs require the RNA chaperone protein Hfq for pairings with target RNAs 20 . In vivo, SprA1 steady-state levels were unaffected by the presence or absence of Hfq (Supplementary Fig. 2c) , suggesting that the protein is dispensable for the interaction between SprA1 AS and SprA1. The cis-overlap between SprA1 and SprA1 AS 3′ ends operated as a bidirectional transcription terminator, presumably for genome compaction and tightness. The 5′ non-overlapping domains of these two asRNAs, however, interacted in trans to repress SprA1-encoded cytolytic peptide synthesis (Fig. 7c) . SprA1 has a compact secondary structure made of RNA pseudoknots flanked by stable stem loops, hindering internal translation initiation signals from the ribosomes. Despite such a structural lock, the S. aureus ribosomes can load onto SprA1 in vitro to produce a 31-amino acid peptide. SprA1 AS is therefore required to block internal translation onto SprA1, inducing a conformational rearrangement by pairing interactions. These observations are consistent with a continuous and tight repression of peptide synthesis that is detrimental for S. aureus growth (data not shown). The SprA1 peptide is probably only expressed under restricted, currently unknown, physiological conditions by specific environmental clues that reduce SprA1 AS levels. The SprA1 AS expression peak at mid-exponential phase suggests that translation repression of SprA1 is optimized during the exponential phase, probably to insure that the lytic peptide is not produced when the S. aureus cells are actively spreading. Alternatively, SprA1 AS could have other functions; it might act in trans on other RNAs. Indeed, in Listeria monocytogenes, riboswitches that are cis-RNA elements can also function in trans, therefore acting as regulatory RNAs 21 . SprA1 could have other functions, possibly at the RNA level, in addition to expressing a peptide. Dual functions, at the transcription and translation levels, have recently been reported for a cytolysin (phenol-soluble modulin, PSM) regulating virulence in S. aureus 22 .
The SprA1 peptide is a previously unknown virulence factor that lyses erythrocytes and probably other eukaryotic cell types and organelles, and it is possibly also involved in erasing competing bacteria. Its function is consistent with its genomic location within a pathogenicity island-containing virulence gene. In order to exert its cytotoxicity, the SprA1 peptide has to interact with target cells. Another S. aureus cytolytic peptide, the δ-hemolysin 23 , is internally encoded within the sRNA RNAIII. The δ-hemolysins are α-helical and amphipatic as predicted for the SprA1 peptide ( Supplementary  Fig. 7) . The δ-hemolysin is active against a wide range of cells and organelles, and enables the phagosomal escape of staphylococci in human cells 24 . Therefore, the SprA1 peptide could also be involved in evading human phagoendosomes, as the acidic pH could lower SprA1 AS levels, leading to SprA1 peptide expression.
Based on sequence comparisons, it has been proposed that SprA1 and SprA1 AS form a type I toxin-antitoxin module resembling those of the long direct repeat in E. coli-Faecalis plasmid stabilization toxin a r t i c l e s (LDR-Fst) family 11 . Type I toxin-antitoxin modules kill cells, usually by forming pores 11 . Some are involved in the general stress response 25 or in specific functions that include controlling production of multidrug-tolerant cells 26 . Here the toxin is internally encoded by an sRNA but not by an mRNA, and protein synthesis is prevented by the sRNA antitoxin in trans. Bacterial type I toxin-antitoxin systems are usually found in multiple copies, and there are up to five copies of sprA in some S. aureus strains 6 , but the systematic coupling of each copy to an asRNA is unknown. However, one difference between the toxin-antitoxin systems and the SprA1-SprA1 AS pair is that in vivo, SprA1 levels are unaffected by increasing SprA1 AS expression. The SprA1-encoded peptide shares physicochemical properties with S. aureus PSMs, which are small, amphipathic and α-helical peptides with substantial cytolytic activity against human neutrophils and erythrocytes 27 . The α-type PSMs also cause chemotaxis and cytokine release. Therefore, similar biological activities are anticipated for the SprA1 peptide. PSMs are regulated by the accessory gene regulator A through its direct interaction with the PSM promoter 28 . By contrast, SprA1 translation is downregulated by an asRNA, as for the toxinantitoxin systems.
In conclusion, cis-antisense RNAs can officiate in trans, suggesting that mechanistic re-evaluations of the identified antisense RNA-mediated target gene regulations in eubacteria, archaea and eukaryotes are needed. Also, a previously unknown virulence factor expressed by S. aureus is reported, and its expression is shown to be locked in vivo by an inhibitory asRNA 
ONLINE METhODS
Strains and plasmids. Strains and plasmids are listed in Supplementary Table 1. S. aureus strains were grown at 37 °C in brain heart infusion broth. When necessary, chloramphenicol and erythromycin were added at 10 µg ml −1 , and kanamycin was added at 200 µg ml −1 . Supplementary Table 2 . In pCN35ΩsprA1 AS , a SprA1 AS sequence with 113 nt upstream and 26 nt downstream was amplified from Newman genomic DNA as a 215-base-pair (bp) fragment, with flanking PstI-EcoRI sites. The fragment is inserted in pCN35. In pCN35ΩSTsprA1-sprA1 AS , the sprA-sprA1 AS locus was amplified from Newman genomic DNA (with 48 nt upstream and 45 nt downstream) with a StreptoTag 16 incorporated between sprA1 and its promoter. For the truncated, flagged SprA1 construct, an sprA1 gene sequence, from positions −171 to +110, was amplified from Newman genomic as a 368-bp fragment flanked by PstI and EcoRI restriction sites in frame with the first 20 amino acids encoded within SprA1; the reverse primer contains 3× Flag (66 bp, 20 amino acids) followed by two 5′-UAG-3′ termination codons. The PCR fragment was inserted into pCN48 (ref. 29) and then digested by PstI-NarI. The resulting 684-bp fragment (truncated sprA1 ending by 3× Flag followed by the blaZ transcription terminator) was inserted into pCN34 (ref. 29). The resulting amino acid sequence of the SprA1 fusion peptide is MLIFVHIIAPVISGC AIAFDYKDHDGDYKDHDIDYKDDDDK. The construction of the deletion mutant S. aureus strain Newman ∆SprA1-SprA1 AS was done as described 30 . Briefly, chromosomal gene disruption of the sprA1-sprA1 AS locus was constructed by deletion of the targeted locus and insertion of an erythromycinresistant gene by using the temperature-sensitive vector pBT2 (ref. 31).
Genetic manipulations. Primers used for all the constructions are listed in
In vitro transcription and RNA labeling. All the RNAs used in this report were transcribed from PCR-amplified templates using Newman genomic DNA. Forward primers contain a T7 promoter sequence (Supplementary Table 2 ). PCR-generated DNA was used as a template for transcription, using the Ambion T7 Megascript kit. For synthesis of short RNAs (SprA1 AS , 5′ SprA1 AS and 3′ SprA1 AS ), a template was produced by annealing the primers listed in Supplementary Table 2. RNAs were gel purified, passively eluted and precipitated with ethanol. The 5′ and 3′ end labeling of the RNAs was carried out as described 13 .
Primer extension and rapid amplification of cDNA end mapping . For SprA1 AS 5′ end mapping, RNA extracts from Newman pCN35ΩsprA1 AS were used. Primer extension was carried out as described 13 , using Superscript III reverse transcriptase. 5′-RACE of SprA1 was carried out as described 13 . Primers for end determination are listed in Supplementary Table 2. RNA extraction and northern blots. Isolated colonies were suspended in 5 ml of brain heart infusion and incubated at 37 °C overnight. The culture was diluted 1:100, then incubated at 37 °C with agitation and stopped at various phases of growth. RNA extraction was carried out as described 32 . The DNA probes used to detect sRNA are listed in Supplementary Table 2 . Total RNA was separated on denaturing PAGE and transferred onto a ZetaProbe GT membrane (Bio-Rad). Specific 32 P-labeled probes were hybridized with ExpressHyb solution (Clontech) for 90 min, washed, exposed and scanned with a PhosphorImager (Molecular Dynamics).
Streptomycin-StreptoTag purification. RNA extracts of Newman ∆sprA1-sprA1 AS pCN35ΩSTsprA1-sprA1 AS were used for affinity purification.
Streptomycin Sepharose preparation and the affinity purification were carried out as described 16 . Eluted RNAs were precipitated with ethanol.
Gel-mobility assays, structural probing and toeprint assays. Gel-mobility assays were carried out as described 13 . An RNA mix was incubated in binding buffer (80 mM K-HEPES, pH 7.5, 4 mM MgCl 2 , 330 mM KCl) before native gel separation. Structural assays were carried out as described 13 . Structural analysis of duplexes between SprA1 and SprA1 AS were prepared by incubating 0.5 pmol of labeled RNA with 1 pmol of unlabeled RNA in binding buffer for 20 min at 30 °C. Digestions with the various RNases were carried out for 15 min at 30 °C in the presence of 1 µg of total tRNA from yeast (V1 at 5 × 10 −5 units, S1 at 5 units and lead acetate at 0.75 mM). The toeprint assays were done as described 30 , with modifications. Purified S. aureus 70S was used and reverse transcription was carried out using labeled primer sprA1Toep (Supplementary Table 2 ).
Protein extractions, western blots and in vitro translation assays. For protein extractions during growth, the pellets were resuspended in lysis buffer (50 mM Tris-HCl, pH 7.5, 3 mM MgCl 2 , 0.1 mg ml −1 lysostaphin and 0.2 U µl −1 of Benzonase), incubated for 15 min at 37 °C, then transferred onto ice. Bradford assays were carried out on the samples, and equal amounts of total proteins were used for the western blots. The samples were separated using 16% tricine-SDS-PAGE 33 , transferred onto a Hybond-P PVDF membrane (Amersham) and identified using the Amersham ECL Plus detection Kit. In vitro translation using [ 35 S]-methionine was carried out with the E. coli S30 extraction system for linear templates (Promega), following the manufacturer's instructions. For the assays in the presence of SprA1 AS or other RNAs, the RNA mix was incubated in binding buffer for 20 min at 30 °C. A 30-pmol aliquot of purified WT SprA1 or SD-mutated SprA1 was used in the presence or absence of 60 pmol of SprA1 AS or 300 pmol of either 5′ SprA1 AS or 3′ SprA1 AS . Samples were separated using 16% tricine-SDS-PAGE 33 . The gel was fixed, exposed and visualized with the PhosphorImager.
Hemolytic assays. For detecting the hemolytic activity of the SprA1 peptide, 100 µL of serial half-dilutions of a PBS buffer solution containing peptides were pipetted into a V-bottom 96-well plate (Sigma). 100 µL of PBS containing 3% (v/v) red blood cells were added to each well and incubated for 1 h at 37 °C. For the hemolysis comparison of human and sheep red blood cells, the cells were washed and diluted to 3% (v/v) in PBS. Human or sheep cells were incubated at 37 °C with either 5 µL of 50% (v/v) isopropanol (negative control) or with 5 µL of 50% (v/v) isopropanol containing 3 nmol of the chemically synthesized SprA1-encoded peptide. 
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